---
title: 'Nivolumab + Ipilimumab as Immunotherapeutic Boost in Metastatic Urothelial
  Carcinoma: A Nonrandomized Clinical Trial'
date: '2024-05-09'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38722641/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240509180930&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'CONCLUSIONS AND RELEVANCE: In this nonrandomized trial, although first-line
  cohort 1 treatment improved objective response rates, considerable progression events
  urge caution with this as a first-line therapy. Second-/third-line cohort 1 treatment
  did not improve response rates compared with nivolumab monotherapy. However, added
  high-dose ipilimumab may improve tumor response and survival in patients with ...'
disable_comments: true
---
CONCLUSIONS AND RELEVANCE: In this nonrandomized trial, although first-line cohort 1 treatment improved objective response rates, considerable progression events urge caution with this as a first-line therapy. Second-/third-line cohort 1 treatment did not improve response rates compared with nivolumab monotherapy. However, added high-dose ipilimumab may improve tumor response and survival in patients with ...